Taurine Supplementation and Exercise on Irisin Levels in Obesity

November 20, 2020 updated by: Ellen Cristini de Freitas, University of Sao Paulo

Effects of Taurine Supplementation Associated With High Intensity Physical Training on Irisin Levels, Energy Expenditure and Body Composition of Obese Women

Irisin is a myocin secreted by skeletal muscle in stimulus to physical exercise and has been described as a possible therapeutic tool in the fight against obesity by triggering a cascade of signaling that triggers the expression of genes responsible for the increase in energy expenditure and browning of adipose tissue white cells by activating thermogenesis promoter mitochondrial proteins. Although the science is engaged in the search for evidences about the actions of the irisin, the physical exercise involved and the improvement in the levels of obesity, many mechanisms are still unknown. Since taurine by means of irisin-like pathways also increases energy expenditure, it is believed that taurine supplementation associated with high intensity aerobic physical exercise can optimize the effects of irisin, increasing energy expenditure and improving body composition in obesity.

Study Overview

Detailed Description

Introduction: Irisin is a myocin secreted by skeletal muscle when stimulated by physical exercise that promotes increased thermogenesis (browning effect). Similarly, taurine is also associated with modulations of energy metabolism with promising actions in the control of metabolic disorders. Thus, it is believed that chronic taurine supplementation associated with physical training can optimize irisin concentrations after exercise.

Objective: Evaluate the effects of taurine supplementation associated with interval aerobic training on plasma irisin concentrations, energy expenditure, body composition and physical fitness in obese women. Methods: Twenty-two women aged 25 to 45 years, sedentary, with grade I obesity (BMI ≥30-35 kg / m²) and without comorbidities will be recruited for the study. The subjects will be submited to a high intensity interval aerobic training for 8 weeks, being 3 times by week, for 50 minutes, associated to the supplementation with 3g of taurine or placebo.

Methods: Assessment of dietary intake, Resting Energy Expenditure (GER) by indirect calorimetry, body composition by deuterium oxide, anthropometric measurements, HPLC plasma analysis of taurine, multiplex irisin and physical fitness variables will be performed pre and post intervention. The results will be expressed as mean and standard deviation and the ANOVA test two way repeated measures mixed model will be applied, with post hoc Sidak, to verify differences and statistical interactions (p <0.05).

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • SP
      • Ribeirão Preto, SP, Brazil
        • Gabriela Batitucci

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 45 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • This study included women with obesity grade I (BMI ≥30 - ≤35Kg/m²), sedentary, with no associated comorbidity, convenience sample.

Exclusion Criteria:

  • Women classified as overweight, obesity grade II and grade III (morbid), who present comorbidities associated with obesity (pre-diabetes, diabetes, hypertension, dyslipidemia, cardiovascular diseases and diseases of bone metabolism); smokers; who use hormones, sports supplements and / or weight loss medications. Perform some type of nutritional monitoring followed by diet or weight loss guidelines and that have medical impediment to the practice of physical exercise.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: OTHER
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Taurine group and exercise
Intervention with taurine supplementation and physical training.
Both groups supplemented with taurine and / or placebo will perform physical training.
There will be a physical training for eight weeks.
PLACEBO_COMPARATOR: Placebo group and exercise
Intervention with placebo supplementation and physical training.
Both groups supplemented with taurine and / or placebo will perform physical training.
There will be a physical training for eight weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes body weight
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
The body weight was measured by digital balance before and after the intervention
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Changes body composition
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
The body composition was evaluated through deuterium oxide
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Changes indirect calorimetry
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
With a gas analyzer (indirect calorimeter), we evaluated the metabolic rate and rest (REE) and oxidation of substrates (lipids and carbohydrates)
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Changes in total cholesterol and lipid fractions
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Collected in EDTA tubes, were centrifuged.
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Changes in plasma taurine concentration
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Collected in EDTA tubes, were centrifuged and the plasma taurine concentration was evaluated using HPLC (high performance liquid chromatography).
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Changes in plasma irisin concentration
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Collected in EDTA tubes, were centrifuged and the plasma irisin concentration was evaluated using Multiplex - Kit Human Myokine Magnetic Bead Panel.
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Changes Food intake
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Food registry of 3 days. The quantification of the daily intake of nutrients will still be made using sofware.
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Changes in determination of lactate
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Blood samples were collected by manual puncture of the earlobe in previously calibrated and heparinized capillary tubes, stored in eppendorf with sodium fluoride. Analyzed by electrochemical lactate analyser.
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Changes Physical Performance
Time Frame: Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention
Maximum effort test, according to Wilder, Brennan e Schotte (1993).
Two times: (1) First day and (2) 10 weeks after assessments, adaptation and intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 1, 2016

Primary Completion (ACTUAL)

May 1, 2016

Study Completion (ACTUAL)

August 1, 2016

Study Registration Dates

First Submitted

November 20, 2020

First Submitted That Met QC Criteria

November 20, 2020

First Posted (ACTUAL)

November 30, 2020

Study Record Updates

Last Update Posted (ACTUAL)

November 30, 2020

Last Update Submitted That Met QC Criteria

November 20, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 51921115500005426

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Taurine group and exercise and placebo group and exercise

Subscribe